EAST BRUNSWICK, N.J., Feb. 7, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's fourth quarter and year-end 2011 financial results will be released prior to the open of the market on Monday, February 27, 2012.
David Y. Norton, Interim Chief Executive Officer, Kenneth J. Zuerblis, Executive Vice President and Chief Financial Officer and Louis Ferrari, Executive Vice President, President North American Commercial Operations will host an investment community conference call beginning at 9:00 a.m. Eastern Time on February 27, 2012 to discuss these results and to answer questions.
To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 49538226. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.
A telephone replay will be available from 12:00 p.m. Eastern Time on February 27, 2012 through 12:00 a.m. Eastern Time on March 7, 2012 by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 49538226.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted
U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.
SOURCE Savient Pharmaceuticals, Inc.